Skip to main content
. 2017 Aug 9;8(39):65699–65716. doi: 10.18632/oncotarget.20081

Figure 5. Epigenetic regulator variations during disease progression.

Figure 5

Sequential samples were selected either from chronic lymphocytic leukemia (CLL) patients evolving from Binet stage A to Binet stage B/C (progressive disease, n = 7), or from CLL patients in Binet stage A at the 2 time points (stable disease, n = 6). Among the 8 epigenetic regulators tested, only DNMT3A, TET2 and SAT1 presented significant differences and are represented in the figure. Statistical differences are indicated by asterisks: (**) 0.001 < P < 0.01; (*) 0.01 < P < 0.05, ns, not significant.